[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656674":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":27,"overallOfficials":13,"centralContacts":33,"locations":13,"responsibleParty":39,"collaborators":41,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":13,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":13,"enrollmentInfo":53,"targetDuration":13,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":65,"whyStopped":13,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":13},{"fullName":5,"class":6},"Jewish General Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Per-Patient GRPR PET\u002FCT Detection Rate","Proportion of participants with at least one GRPR-positive lesion on \\[⁶⁸Ga\\]-LY4257529 PET\u002FCT. Detection rate will be calculated as the number of participants with at least one GRPR-positive lesion divided by the total number of participants in the relevant cancer cohort.","After the PET\u002FCT imaging is completed",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":24,"interventionNames":25},"[⁶⁸Ga]-GRPR PET\u002FCT","EXPERIMENTAL","Participants with breast cancer or other selected GRPR-expressing malignancies will receive a single intravenous administration of approximately 170 MBq ±20% of \\[⁶⁸Ga\\]-LY4257529, followed by PET\u002FCT imaging approximately 50-70 minutes after injection. All participants undergo the same imaging intervention.",[26],"Diagnostic Test: GRPR PET\u002FCT",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":13},"DIAGNOSTIC_TEST","GRPR PET\u002FCT","\\[⁶⁸Ga\\]-LY4257529 is an investigational gastrin-releasing peptide receptor (GRPR)-targeted PET radiopharmaceutical. Participants will receive approximately 170 MBq ±20% (4.6 mCi ±20%) intravenously. PET\u002FCT imaging will begin approximately 50-70 minutes after administration to evaluate GRPR-targeted tumor uptake and distribution.",[22],[34],{"name":35,"role":36,"phone":37,"phoneExt":13,"email":38},"Gad Abikhzer","CONTACT","514-340-8222","gad.abikhzer@mcgill.ca",{"type":40,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[42],{"name":43,"class":44},"Eli Lilly and Company","INDUSTRY","100656674","early-phase-1-petct-imaging-of-grpr-expression-in-various-tumors-100656674",false,"NCT07828678","PET\u002FCT Imaging of GRPR Expression in Various Tumors","Inclusion Criteria:\n\nAge 18 years or older Able to understand and provide written informed consent\n\nDiagnosis of a breast cancer or other tumor known or suspected to express GRPR, including:\n\nER-positive\u002FHER2-negative breast cancer Invasive lobular breast cancer Head and neck squamous cell carcinoma Small-cell lung cancer Ovarian cancer Prostate cancer with biochemical recurrence and a negative PSMA PET\u002FCT Metastatic pancreatic cancer after pancreatic surgery Other tumor with GRPR expression demonstrated on histopathology ECOG performance status 0-3 Under the care of a referring physician Able to tolerate PET\u002FCT imaging, including lying supine for up to 30 minutes with arms above the head and intravenous cannulation\n\nExclusion Criteria:\n\nTumor type known in the literature not to express GRPR, unless patient-specific tissue demonstrates GRPR expression Medically unstable condition, including acute cardiac or respiratory distress or hypotension Weight exceeding PET\u002FCT table limit of 200 kg or inability to fit within the 70-cm PET\u002FCT bore Unmanageable claustrophobia Known allergic or hypersensitivity reaction to a prior GRPR-targeting radioligand such as ⁶⁸Ga-RM2 or bombesin analogues Pregnancy Lactation For individuals of childbearing potential, inability to document a negative pregnancy test before tracer administration","ALL","18 Years",{"count":54,"type":55},60,"ESTIMATED","INTERVENTIONAL",[58],"EARLY_PHASE1","This open-label imaging study will evaluate \\[⁶⁸Ga\\]-LY4257529 PET\u002FCT, a gastrin-releasing peptide receptor (GRPR)-targeted radiopharmaceutical, in patients with cancers known or suspected to express GRPR. Up to 60 participants will be enrolled in two cohorts: 30 patients with breast cancer and 30 patients with other selected malignancies, including prostate, ovarian, pancreatic, small-cell lung, head and neck squamous cell carcinoma, and other tumors with documented GRPR expression.",[61],"Malignancies Multiple",[63,64],"GRPR","PET\u002FCT","NOT_YET_RECRUITING","2026-09-15",{"date":68,"type":69},"2026-09-18","ACTUAL",{"date":71,"type":55},"2026-11",{"date":73,"type":55},"2029-06",{"name":5,"class":6}]